Newsbenzinga
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill
· Published
Article summary
Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.
An excerpt from the original article.
Comments —
Loading comments…